Stock Ratings / Health Care / CMMB / financials

PTN (38) INM (47) ENSC (35) MBRX (43) ⌘ Pro Terminal →

Chemomab Therapeutics Ltd. (CMMB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.09 -0.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

Chemomab Therapeutics Ltd. (CMMB) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $8.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.09 (-0.35%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMMB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY CMMB SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 36.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.38-8.7% Next Q

Q2 (-2Q)

Grade D$1.26-18.3% Next Q

Q3 (-1Q)

Grade D$1.03+5.8% Next Q

Current

Grade D-$1.09-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMMB currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.90) and Max Pain ($1.14) forces dealer call-delta covering toward $3.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CMMB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CMMB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-2.8%	-$9.0M	-$11.1M	-45%
FY 2024	$4.00B	52%	-2.6%	-$13.9M	-$15.4M	-45%
FY 2023	$4.00B	52%	0%	-$24.2M	-$23.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMMB)

✓Walkthrough of CMMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CMMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.85%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.14H $1.16L $1.01C $1.09VOL 224.5K

RES: $3.18SUP: $0.90SMA50: $1.90SMA200: $1.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMMB Butterfly Map → + Track CMMB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CMMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CMMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMMB)

Health Care Rank #731 of 1016 ⚔️ PTN vs CMMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMMB vs. PTN, INM, ENSC, MBRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Chemomab Therapeutics Ltd. (CMMB) ranks #731 by composite RQD confidence (38/100, grade D-) and #907 by equity capitalization ($8.8M). Within this direct 5-issuer industry benchmark cohort, CMMB leads on earnings valuation at N/A trailing P/E, while CMMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CMMB at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CMMB ACTIVE Chemomab Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-0.91%	$8.8M	Benchmark Subject
PTN Palatin Technologies Inc.	D-	38/100	—	—	-35.0%	-3.33%	$8.8M	/ptn-vs-cmmb →
INM InMed Pharmaceuticals Inc.	D	47/100	—	34.5%	-35.0%	+1.61%	$8.9M	/inm-vs-cmmb →
ENSC Ensysce Biosciences Inc.	D-	35/100	—	—	-35.0%	-3.16%	$8.5M	/ensc-vs-cmmb →
MBRX Moleculin Biotech Inc.	D-	43/100	—	—	-35.0%	-0.29%	$9.2M	/mbrx-vs-cmmb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534248

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Chemomab Therapeutics Ltd. (CMMB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$9.0M, operating cash flow of -$11.1M, and free cash flow of -$11.1M (+27.6% YoY). On the balance sheet, CMMB closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$9.0M	-$11.1M	-$11.1M	$13.8M	—
FY2024 (FY)	2024-12-31	$0	-$13.9M	-$15.4M	-$15.4M	$17.0M	—
FY2023 (FY)	2023-12-31	$0	-$24.2M	-$23.6M	-$23.6M	—	—

3. CMMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.09 (-0.91% 1D, market cap $8.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CMMB ranks #731 in composite RQD confidence.

How does CMMB compare to PTN and INM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMMB carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PTN (Palatin Technologies Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and INM (InMed Pharmaceuticals Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $8.9M). Among the 5-stock peer group, CMMB leads on earnings multiple (N/A) while CMMB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CMMB?

Per CMMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534248), Chemomab Therapeutics Ltd. generated $0 in revenue, -$9.0M in net income, and -$11.1M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CMMB trading relative to its 50-day, 200-day, and 52-week technical levels?

CMMB last traded at $1.09 (-0.91% on volume of 41,050 shares), positioning the stock -42.63% below its 50-day simple moving average ($1.90) and -37.71% below its 200-day simple moving average ($1.75). Across its 52-week range of $0.92 to $3.07, CMMB sits at the 7.9% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.23).

CMMB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Chemomab Therapeutics Ltd. (CMMB)?

In FY 2025 (10-K), CMMB converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CMMB RQD Cockpit CMMB 12M Forecast CMMB Earnings & Move CMMB Dividends & DRIP CMMB Insiders & 13F CMMB Whale Options CMMB Profit Sankey CMMB News & Why